Lineage Cell Therapeutics (LCTX) Preferred Dividend Payments (2014 - 2015)
Lineage Cell Therapeutics (LCTX) posted quarterly Preferred Dividend Payments of -$830000.0 for Q4 2015, down 1666.04% year-over-year from $53000.0 in Q4 2014, and down 328.65% quarter-over-quarter from $363000.0 in Q3 2015.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Preferred Dividend Payments (2014 - 2015) Analysis & Trends
Lineage Cell Therapeutics' Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at -$830000.0 for Q4 2015.
- In Q4 2015, Preferred Dividend Payments fell 1666.04% year-over-year to -$830000.0; the TTM figure through Dec 2016 stood at -$830000.0 (down 129.28% YoY), while the FY2015 annual figure was -$415000.0, down 577.01% from the prior year.
- Preferred Dividend Payments for Q4 2015 stood at -$830000.0, down from $363000.0 in the prior quarter.
- The five-year high for Preferred Dividend Payments was $363000.0 in Q3 2015, with the low at -$830000.0 in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2015 | -830,000.00 |
| Sep 30, 2015 | 363,000.00 |
| Jun 30, 2015 | 52,000.00 |
| Dec 31, 2014 | 53,000.00 |
| Sep 30, 2014 | 34,000.00 |
| Jun 30, 2014 | 34,000.00 |